Mobile App-Based Remote Management Model for IBD Patient

Launched by CHANGHAI HOSPITAL · Jul 16, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how a mobile app can help manage Inflammatory Bowel Disease (IBD) for patients in China. IBD is a long-term condition that causes inflammation in the intestines, and managing it effectively is crucial for improving patients' quality of life. The study aims to understand how aware patients are about their condition and their needs regarding telemedicine, which is the use of technology to provide medical care remotely. It will also work on creating a system using a mobile app to help monitor symptoms and provide support to patients, and will look at how this approach affects their health and use of healthcare services.

To participate in this trial, individuals must be diagnosed with IBD and be between the ages of 18 and 75. They should have had at least one flare-up of their condition in the last two years. However, those with a history of surgery for IBD, certain medical issues, or who are pregnant cannot take part. Participants can expect to engage with the mobile app, which may help improve their understanding of their condition and assist in managing their health more effectively. This study is an important step toward enhancing care for IBD patients in China through innovative technology.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients will be diagnosed with IBD based on the diagnostic criteria outlined in the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease (2018, Beijing)". The diagnosis will be established by combining clinical symptoms, endoscopic examination results, imaging findings, and histological examination results.
• • 2. Participants must be between the ages of 18 and 75 and provide signed informed consent for the project.
• • 3. Within the two years prior to enrollment, medical records must show at least one instance assessed as an inflammatory active phase (Mayo score ≥ 3 or CDAI score ≥ 150).
• Exclusion Criteria:
• • 1. Participants deemed unable to adhere to the study protocol as determined by the investigators.
• • 2. Individuals with a history of surgical treatment for IBD or those scheduled to undergo surgery.
• • 3. Uncontrolled internal medicine or psychiatric disorders.
• • 4. Pregnant individuals or those planning to become pregnant during the enrollment and follow-up period.